Voyager Therapeutics to Present VY1706 Alzheimer's Gene Therapy Study Design at CTAD 2026

PUBT · 2d ago
Voyager Therapeutics to Present VY1706 Alzheimer's Gene Therapy Study Design at CTAD 2026
  • Voyager Therapeutics will present Alzheimer's study posters Nov. 16-17 at CTAD 2026, held Nov. 16-19 in Boston.
  • VY1706's presentation will outline a first-in-human study of the gene therapy designed to lower tau production in early Alzheimer's disease.
  • The VY7523 poster will describe baseline participant characteristics in a multiple ascending dose study of the anti-tau antibody in early Alzheimer's disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Voyager Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610270801PRIMZONEFULLFEED9853763) on October 27, 2026, and is solely responsible for the information contained therein.